+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Rituximab Biosimilars Global Market Opportunities and Strategies to 2030: COVID 19 Growth and Change

  • ID: 5353043
  • Report
  • June 2021
  • Region: Global
  • The Business Research Company

FEATURED COMPANIES

  • Amgen
  • Cadila Pharmaceuticals
  • Dr Reddy’s Laboratories
  • Innovent Biologics, Inc
  • mAbxience
  • Pfizer
  • MORE

Rituximab Biosimilars Global Market Opportunities and Strategies to 2030: COVID-19 Growth and Change provides the strategists, marketers and senior management with the critical information they need to assess the global rituximab biosimilar market as it emerges from the COVID-19 shut down.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 12+ geographies.
  • Understand how the market is being affected by the coronavirus and how it is likely to emerge and grow as the impact of the virus abates.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market research findings.
  • Benchmark performance against key competitors.
  • Utilize the relationships between key data sets for superior strategizing.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis

Description:

Where is the largest and fastest growing market for the rituximab biosimilar? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The Rituximab biosimilar market global report answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography. It places the market within the context of the wider rituximab biosimilar market, and compares it with other markets.

The report covers the following chapters:

  • Executive Summary - The executive summary section of the report gives a brief overview and summary of the report.
  • Report Structure - This section gives the structure of the report and the information covered in various sections.
  • Introduction - This section gives the segmentation of the rituximab biosimilars market by geography, by drug type, by application and by route of administration covered in this report.
  • Market Characteristics - The market characteristics section of the report defines and explains the rituximab biosimilars market. This chapter includes different products and services covered in the report and basic definitions.
  • Trends and Strategies - This chapter includes some of the major trends shaping the global rituximab biosimilars market. This section highlights likely future developments in the market and suggests approaches companies can take to exploit these opportunities.
  • Impact of COVID-19 - This chapter describes the impact of COVID-19 on the rituximab biosimilars industry.
  • Global Market Size and Growth - This section contains the global historic (2015-2020) and forecast (2020-2025) market value, and drivers and restraints that support and control the growth of the market in the historic and forecast period.
  • Regional Analysis - This section contains the historic (2015-2020), forecast (2020-2025) market value and growth, and market share comparison by region.
  • Segmentation - This section contains the market value (2015-20) and analysis for different segments.
  • Regional Market Size and Growth - This section contains the region’s market size (2020), historic (2015-2020) and forecast (2020-2025) market value, and growth and market share comparison of major countries within the region. This report includes information on all the regions Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa and major countries within each region. The market overview sections of the report describe the current size of the market, background information, government initiatives, regulations, regulatory bodies, associations, corporate tax structure, investments, and major companies.
  • Competitive Landscape - This section covers details on the competitive landscape of the global rituximab biosimilars market, estimated market shares and company profiles for the leading players.
  • Key Mergers and Acquisitions - This chapter gives the information on recent mergers and acquisitions in the market covered in the report. This section gives key financial details of mergers and acquisitions, which have shaped the market in recent years.
  • Opportunities and Strategies - This section gives information on growth opportunities across countries, segments and strategies to be followed in those markets. It gives an understanding of where there is significant business to be gained by competitors in the next five years.
  • Conclusions and Recommendations - This section includes conclusions and recommendations based on the findings of the research. This section also gives recommendations for rituximab biosimilars companies in terms of product offerings, geographic expansion, price offerings, and target groups.
  • Appendix - This section includes details on the NAICS codes covered, abbreviations and currencies codes used in this report.

Scope

Markets Covered:

1) By Application: Non-Hodgkin's lymphoma; Chronic lymphocytic leukemia; Rheumatoid arthritis; Others
2) By Distribution Channel: Hospital pharmacy; Mail order; Retail pharmacy

Companies Mentioned: Teva/Cellitron; Novartis AG; Pfizer; BIOCAD; Shanghai Henluis Biotech Inc.

Metrics Covered: Number of Enterprises; Number of Employees

Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; United States

Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa

Time series: Five years historic and ten years forecast.

Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita, rituximab biosimilar indicators comparison.

Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.

Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.

Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Amgen
  • Cadila Pharmaceuticals
  • Dr Reddy’s Laboratories
  • Innovent Biologics, Inc
  • mAbxience
  • Pfizer
  • MORE

1. Rituximab Biosimilars Market Executive Summary

2. Table of Contents

3. List of Figures

4. List of Tables

5. Report Structure

6. Introduction
6.1.1. Segmentation By Geography
6.1.2. Segmentation By Application
6.1.3. Segmentation By Distribution Channel

7. Rituximab Biosimilars Market Characteristics
7.1. Market Definition
7.2. Market Segmentation By Application
7.2.1. Non-Hodgkin’s Lymphoma
7.2.2. Chronic Lymphocytic Leukemia
7.2.3. Rheumatoid Arthritis
7.2.4. Others
7.3. Market Segmentation By Distribution Channel
7.3.1. Retail Pharmacy
7.3.2. Hospital Pharmacy
7.3.3. Mail Order

8. Rituximab Biosimilars Market Trends and Strategies
8.1. Revised FDA Regulations To Facilitate Biosimilar Drug Development
8.2. Large Number Of Strategic Partnerships and Collaborations.
8.3. Robust Research & Development

9. Impact Of COVID-19 On The Rituximab Biosimilars Market
9.1. Impact On The Global Rituximab Biosimilars Market
9.2. How Leading Rituximab Biosimilars Companies Handled COVID

10. Global Rituximab Biosimilars Market Size and Growth
10.1. Market Size
10.2. Historic Market Growth, 2015 - 2020, Value ($ Million)
10.2.1. Drivers Of The Market 2015 - 2020
10.2.2. Restraints On The Market 2015 - 2020
10.3. Forecast Market Growth, 2020 - 2025, 2030F, Value ($ Million)
10.3.1. Drivers Of The Market 2020 - 2025
10.3.2. Restraints On The Market 2020 - 2025

11. Global Rituximab Biosimilars Market Segmentation
11.1. Global Rituximab Biosimilars Market, Segmentation By Application, Historic and Forecast, 2015 - 2020, 2025F, 2030F, Value ($ Million)
11.1.1. Non-Hodgkin’s Lymphoma
11.1.2. Chronic Lymphocytic Leukemia
11.1.3. Rheumatoid Arthritis
11.1.4. Others
11.2. Global Rituximab Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2015 - 2020, 2025F, 2030F, Value ($ Million)
11.2.1. Hospital Pharmacy
11.2.2. Retail Pharmacies
11.2.3. Mail Order

12. Rituximab Biosimilars Market, Regional and Country Analysis
12.1. Global Rituximab Biosimilars Market, By Region, Historic and Forecast, 2015 - 2020, 2025F, 2030F, Value ($ Million)
12.2. Global Rituximab Biosimilars Market, By Country, Historic and Forecast, 2015 - 2020, 2025F, 2030F, Value ($ Million)

13. Asia-Pacific Rituximab Biosimilars Market
13.1. Asia-Pacific Rituximab Biosimilars Market Overview
13.1.1. Region Information
13.1.2. Market Information
13.1.3. COVID-19 Impact
13.1.4. Background Information
13.1.5. Government Initiatives
13.1.6. Regulations
13.1.7. Regulatory Bodies
13.1.8. Major Associations
13.1.9. Taxes Levied
13.1.10. Corporate Tax Structure
13.1.11. Investments
13.1.12. Major Companies
13.2. Asia-Pacific Rituximab Biosimilars Market, Historic Market Growth, 2015 - 2020, Value ($ Million)
13.3. Asia-Pacific Rituximab Biosimilars Market, Forecast Market Growth, 2020 - 2025, 2030F, Value ($ Million)
13.4. Asia-Pacific Rituximab Biosimilars Market, Segmentation By Application, Historic and Forecast, 2015 - 2020, 2025F, 2030F, Value ($ Million)
13.5. Asia-Pacific Rituximab Biosimilars Market: Country Analysis
13.6. China Rituximab Biosimilars Market
13.7. China Rituximab Biosimilars Market Overview
13.8. China Rituximab Biosimilars Market Overview
13.8.1. Country Information
13.8.2. Market Information
13.8.3. COVID-19 Impact
13.8.4. Background information
13.8.5. Government Initiatives
13.8.6. Regulations
13.8.7. Regulatory Bodies
13.8.8. Major Associations
13.8.9. Taxes levied
13.8.10. Corporate tax structure
13.8.11. Investments
13.8.12. Major Companies
13.9. China Rituximab Biosimilars Market, Historic Market Growth, 2015 - 2020, Value ($ Million)
13.10. China Rituximab Biosimilars Market, Forecast Market Growth, 2020 - 2025, 2030F, Value ($ Million)
13.11. China Rituximab Biosimilars Market, Segmentation By Application, Historic and Forecast, 2015 - 2020, 2025F, 2030F, Value ($ Million)
13.12. India Rituximab Biosimilars Market
13.13. India Rituximab Biosimilars Market Overview
13.13.1. Country Information
13.13.2. Market Information
13.13.3. COVID-19 Impact
13.13.4. Background Information
13.13.5. Government Initiatives
13.13.6. Regulations
13.13.7. Regulatory Bodies
13.13.8. Major Associations
13.13.9. Taxes Levied
13.13.10. Corporate Tax Structure
13.13.11. Investments
13.13.12. Major Companies
13.14. India Rituximab Biosimilars Market, Historic Market Growth, 2015 - 2020, Value ($ Million)
13.15. India Rituximab Biosimilars Market, Forecast Market Growth, 2020 - 2025, 2030F, Value ($ Million)
13.16. India Rituximab Biosimilars Market, Segmentation By Application, Historic and Forecast, 2015 - 2020, 2025F, 2030F, Value ($ Million)
13.17. Japan Rituximab Biosimilars Market
13.18. Japan Rituximab Biosimilars Market Overview
13.18.1. Country Information
13.18.2. Market Information
13.18.3. COVID-19 Impact
13.18.4. Background Information
13.18.5. Government Initiatives
13.18.6. Regulations
13.18.7. Regulatory Bodies
13.18.8. Major Associations
13.18.9. Taxes Levied
13.18.10. Corporate Tax Structure
13.18.11. Investments
13.18.12. Major Companies
13.19. Japan Rituximab Biosimilars Market, Historic Market Growth, 2015 - 2020, Value ($ Million)
13.20. Japan Rituximab Biosimilars Market, Forecast Market Growth, 2020 - 2025, 2030F, Value ($ Million)
13.21. Japan Rituximab Biosimilars Market, Segmentation By Application, Historic and Forecast, 2015 - 2020, 2025F, 2030F, Value ($ Million)
13.22. Australia Rituximab Biosimilars Market
13.23. Australia Rituximab Biosimilars Market, Historic Market Growth, 2015 - 2020, Value ($ Million)
13.24. Australia Rituximab Biosimilars Market, Forecast Market Growth, 2020 - 2025, 2030F, Value ($ Million)
13.25. Australia Rituximab Biosimilars Market, Segmentation By Application, Historic and Forecast, 2015 - 2020, 2025F, 2030F, Value ($ Million)
13.26. Indonesia Rituximab Biosimilars Market
13.27. Indonesia Rituximab Biosimilars Market, Forecast Market Growth, 2020 - 2025, 2030F, Value ($ Million)
13.28. Indonesia Rituximab Biosimilars Market, Segmentation By Application, Historic and Forecast, 2015 - 2020, 2025F, 2030F, Value ($ Million)
13.29. South Korea Rituximab Biosimilars Market
13.30. South Korea Rituximab Biosimilars Market, Historic Market Growth, 2015 - 2020, Value ($ Million)
13.31. South Korea Rituximab Biosimilars Market, Forecast Market Growth, 2020 - 2025, 2030F, Value ($ Million)
13.32. South Korea Rituximab Biosimilars Market, Segmentation By Application, Historic and Forecast, 2015 - 2020, 2025F, 2030F, Value ($ Million)

14. Western Europe Rituximab Biosimilars Market
14.1. Western Europe Rituximab Biosimilars Market Overview
14.1.1. Region Information
14.1.2. Market Information
14.1.3. COVID-19 Impact
14.1.4. Background Information
14.1.5. Government Initiatives
14.1.6. Regulations
14.1.7. Regulatory Bodies
14.1.8. Major Associations
14.1.9. Taxes Levied
14.1.10. Corporate Tax Structure
14.1.11. Investments
14.1.12. Major Companies
14.2. Western Europe Rituximab Biosimilars Market, Historic Market Growth, 2015 - 2020, Value ($ Million)
14.3. Western Europe Rituximab Biosimilars Market, Forecast Market Growth, 2020 - 2025, 2030F, Value ($ Million)
14.4. Western Europe Rituximab Biosimilars Market, Segmentation By Application, Historic and Forecast, 2015 - 2020, 2025F, 2030F, Value ($ Million)
14.5. Western Europe Rituximab Biosimilars Market: Country Analysis
14.6. UK Rituximab Biosimilars Market
14.7. UK Rituximab Biosimilars Market Overview
14.7.1. Country Information
14.7.2. Market Information
14.7.3. COVID-19 Impact
14.7.4. Background Information
14.7.5. Government Initiatives
14.7.6. Regulations
14.7.7. Regulatory Bodies
14.7.8. Major Associations
14.7.9. Taxes Levied
14.7.10. Corporate Tax Structure
14.7.11. Investments
14.7.12. Major Companies
14.8. UK Rituximab Biosimilars Market, Historic Market Growth, 2015 - 2020, Value ($ Million)
14.9. UK Rituximab Biosimilars Market, Forecast Market Growth, 2020 - 2025, 2030F, Value ($ Million)
14.10. UK Rituximab Biosimilars Market, Segmentation By Application, Historic and Forecast, 2015 - 2020, 2025F, 2030F, Value ($ Million)
14.11. Germany Rituximab Biosimilars Market
14.12. Germany Rituximab Biosimilars Market, Historic Market Growth, 2015 - 2020, Value ($ Million)
14.13. Germany Rituximab Biosimilars Market, Forecast Market Growth, 2020 - 2025, 2030F, Value ($ Million)
14.14. Germany Rituximab Biosimilars Market, Segmentation By Application, Historic and Forecast, 2015 - 2020, 2025F, 2030F, Value ($ Million)
14.15. France Rituximab Biosimilars Market
14.16. France Rituximab Biosimilars Market, Historic Market Growth, 2015 - 2020, Value ($ Million)
14.17. France Rituximab Biosimilars Market, Forecast Market Growth, 2020 - 2025, 2030F, Value ($ Million)
14.18. France Rituximab Biosimilars Market, Segmentation By Application, Historic and Forecast, 2015 - 2020, 2025F, 2030F, Value ($ Million)

15. Eastern Europe Rituximab Biosimilars Market
15.1. Eastern Europe Rituximab Biosimilars Market Overview
15.1.1. Region Information
15.1.2. Market Information
15.1.3. COVID-19 Impact
15.1.4. Background Information
15.1.5. Government Initiatives
15.1.6. Regulations
15.1.7. Regulatory Bodies
15.1.8. Associations
15.1.9. Taxes levied
15.1.10. Corporate Tax Structure
15.1.11. Investment
15.1.12. Major Companies
15.2. Eastern Europe Rituximab Biosimilars Market, Historic Market Growth, 2015 - 2020, Value ($ Million)
15.3. Eastern Europe Rituximab Biosimilars Market, Forecast Market Growth, 2020 - 2025, 2030F, Value ($ Million)
15.4. Eastern Europe Rituximab Biosimilars Market, Segmentation By Application, Historic and Forecast, 2015 - 2020, 2025F, 2030F, Value ($ Million)
15.5. Eastern Europe Rituximab Biosimilars Market: Country Analysis
15.6. Russia Rituximab Biosimilars Market
15.7. Russia Rituximab Biosimilars Market, Historic Market Growth, 2015 - 2020, Value ($ Million)
15.8. Russia Rituximab Biosimilars Market, Forecast Market Growth, 2020 - 2025, 2030F, Value ($ Million)
15.9. Russia Rituximab Biosimilars Market, Segmentation By Application, Historic and Forecast, 2015 - 2020, 2025F, 2030F, Value ($ Million)

16. North America Rituximab Biosimilars Market
16.1. North America Rituximab Biosimilars Market Overview
16.1.1. Region Information
16.1.2. Market Information
16.1.3. COVID 19 Impact
16.1.4. Background Information
16.1.5. Government Initiatives
16.1.6. Regulations
16.1.7. Regulatory Bodies
16.1.8. Major Associations
16.1.9. Taxes Levied
16.1.10. Corporate Tax Structure
16.1.11. Investments
16.1.12. Major Companies
16.2. North America Rituximab Biosimilars Market, Historic Market Growth, 2015 - 2020, Value ($ Million)
16.3. North America Rituximab Biosimilars Market, Forecast Market Growth, 2020 - 2025, 2030F, Value ($ Million)
16.4. North America Rituximab Biosimilars Market, Segmentation By Application, Historic and Forecast, 2015 - 2020, 2025F, 2030F, Value ($ Million)
16.5. North America Rituximab Biosimilars Market: Country Analysis
16.6. USA Rituximab Biosimilars Market
16.7. USA Rituximab Biosimilars Market Overview
16.7.1. Country Information
16.7.2. Market Information
16.7.3. COVID 19 Impact
16.7.4. Background Information
16.7.5. Government Initiatives
16.7.6. Regulations
16.7.7. Regulatory Bodies
16.7.8. Major Associations
16.7.9. Tax Levied
16.7.10. Corporate Tax Structure
16.7.11. Investments
16.7.12. Major Companies
16.8. USA Rituximab Biosimilars Market, Historic Market Growth, 2015 - 2020, Value ($ Million)
16.9. USA Rituximab Biosimilars Market, Forecast Market Growth, 2020 - 2025, 2030F, Value ($ Million)
16.10. USA Rituximab Biosimilars Market, Segmentation By Application, Historic and Forecast, 2015 - 2020, 2025F, 2030F, Value ($ Million)

17. South America Rituximab Biosimilars Market
17.1. South America Rituximab Biosimilars Market Overview
17.1.1. Region Information
17.1.2. Market Information
17.1.3. COVID-19 Impact
17.1.4. Background Information
17.1.5. Government Initiatives
17.1.6. Regulations
17.1.7. Regulatory Bodies
17.1.8. Major Associations
17.1.9. Taxes levied
17.1.10. Corporate Tax Structure
17.1.11. Investments
17.1.12. Major Companies
17.2. South America Rituximab Biosimilars Market, Historic Market Growth, 2015 - 2020, Value ($ Million)
17.3. South America Rituximab Biosimilars Market, Forecast Market Growth, 2020 - 2025, 2030F, Value ($ Million)
17.4. South America Rituximab Biosimilars Market, Segmentation By Application, Historic and Forecast, 2015 - 2020, 2025F, 2030F, Value ($ Million)
17.5. South America Rituximab Biosimilars Market: Country Analysis
17.6. Brazil Rituximab Biosimilars Market
17.7. Brazil Rituximab Biosimilars Market, Historic Market Growth, 2015 - 2020, Value ($ Million)
17.8. Brazil Rituximab Biosimilars Market, Forecast Market Growth, 2020 - 2025, 2030F, Value ($ Million)
17.9. Brazil Rituximab Biosimilars Market, Segmentation By Application, Historic and Forecast, 2015 - 2020, 2025F, 2030F, Value ($ Million)

18. Middle East Rituximab Biosimilars Market
18.1. Middle East Rituximab Biosimilars Market Overview
18.1.1. Region Information
18.1.2. COVID 19 impact
18.1.3. Background Information
18.1.4. Government Initiatives
18.1.5. Regulations
18.1.6. Regulatory Bodies
18.1.7. Major Associations
18.1.8. Taxes Levied
18.1.9. Corporate Tax Structure
18.1.10. Investments
18.1.11. Major Companies
18.2. Middle East Rituximab Biosimilars Market, Forecast Market Growth, 2020 - 2025, 2030F, Value ($ Million)
18.3. Middle East Rituximab Biosimilars Market, Segmentation By Application, Historic and Forecast, 2015 - 2020, 2025F, 2030F, Value ($ Million)

19. Africa Rituximab Biosimilars Market
19.1. Africa Rituximab Biosimilars Market Overview
19.1.1. Region Information
19.1.2. COVID-19 impact
19.1.3. Background Information
19.1.4. Government Initiatives
19.1.5. Regulations
19.1.6. Regulatory Bodies
19.1.7. Associations
19.1.8. Taxes levied
19.1.9. Corporate Tax Structure
19.1.10. Investments
19.1.11. Major Companies
19.2. Africa Rituximab Biosimilars Market, Forecast Market Growth, 2020 - 2025, 2030F, Value ($ Million)
19.3. Africa Rituximab Biosimilars Market, Segmentation By Application, Historic and Forecast, 2015 - 2020, 2025F, 2030F, Value ($ Million)

20. Global Rituximab Biosimilars Market Competitive Landscape
20.1. Company Profiles
20.2. Teva Pharmaceuticals
20.2.1. Company Overview
20.2.2. Products and Services
20.2.3. Business Strategy
20.2.4. Financial Overview
20.3. Novartis AG
20.3.1. Company Overview
20.3.2. Products and Services
20.3.3. Financial Overview
20.4. Pfizer
20.4.1. Company Overview
20.4.2. Products and Services
20.4.3. Business Strategy
20.4.4. Financial overview
20.5. BIOCAD
20.5.1. Company Overview
20.5.2. Products and Services
20.5.3. Business Strategy
20.5.4. Financial Overview
20.6. Shanghai Henlius Biotech, Inc.
20.6.1. Company Overview
20.6.2. Products and Services
20.6.3. Business Strategy
20.6.4. Financial Overview

21. Key Mergers and Acquisitions In The Rituximab Biosimilars Market
21.1. Innovent Biologics and Eli Lilly and Company Collaboration
21.2. Teva Pharmaceuticals and Celltrion Healthcare Jointly Launched TRUXIMA
21.3. Coherus Biosciences Acquired Rights From Innovent Biologics
21.4. Ibio, Inc. Collaborated With CC-Pharming Ltd.
21.5. Torrent Pharmaceuticals Collaborated with Reliance Life Sciences
21.6. Forty Seven Inc. Collaborated With Acerta Pharma
21.7. Sanofi Partnered with JHL Biotech

22. Rituximab Biosimilars Market
22.1. Global Rituximab Biosimilars Market In 2025 - Countries Offering Most New Opportunities
22.2. Global Rituximab Biosimilars Market In 2025 - Segments Offering Most New Opportunities
22.3. Global Rituximab Biosimilars Market In 2025 - Growth Strategies
22.3.1. Market Trend Based Strategies
22.3.2. Competitor Strategies

23. Rituximab Biosimilars, Conclusions and Recommendations
23.1. Conclusions
23.2. Recommendations
23.2.1. Product
23.2.2. Place
23.2.3. Price
23.2.4. Promotion
23.2.5. People

24. Appendix
24.1. Market Data Sources
24.2. Research Methodology
24.3. Currencies
24.4. Research Inquiries
24.5. About the Publisher
24.6. Copyright and Disclaimer

Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Amgen
  • Cadila Pharmaceuticals
  • Dr Reddy’s Laboratories
  • Innovent Biologics, Inc
  • mAbxience
  • Pfizer
  • MORE

This report describes and explains the rituximab biosimilar market and covers 2015 to 2020, termed the historic period, and 2020 to 2025 termed the forecast period, along with further forecasts for the period 2025-2030. The report evaluates the market across each region and for the major economies within each region.

The rituximab biosimilar market reached a value of nearly $1,602.1 million in 2020, having increased at a compound annual growth rate (CAGR) of 67.9% since 2015. The market is expected to grow from $1,602.1 million in 2020 to $3,474.2 million in 2025 at a rate of 16.7%. The market is then expected to grow at a CAGR of 10.5% from 2025 and reach $5,723.6 million in 2030.

Growth in the historic period resulted from government initiatives, increased healthcare expenditure, increase in biopharmaceutical R&D expenditure, low cost of biosimilars, and emerging markets growth. Factors that negatively affected growth in the historic period were the effect of COVID-19, the low number of drug approvals, and the lack of awareness of biosimilars among primary care physicians and specialists.

Going forward, aging population, increase in healthcare access, and rising prevalence of chronic diseases will drive the growth. Factors that could hinder the growth of the rituximab biosimilar market in the future include stringent regulations related to biosimilar approvals, and prolonged production and approval time.

The rituximab biosimilar market is segmented by application into non-Hodgkin's lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, and others. The non-Hodgkin's lymphoma was the largest segment of the rituximab biosimilar market segmented by application, accounting for 28.5% of the total in 2020. Going forward, the rheumatoid arthritis segment is expected to be the fastest growing segment in the rituximab biosimilar market segmented by application, at a CAGR of 18.3% during 2020-2025.

The rituximab biosimilar market is also segmented by distribution channel into hospital pharmacy, mail order and retail pharmacy. The hospital pharmacy was the largest segment of the rituximab biosimilar market segmented by distribution channel, accounting for 87.7% of the total in 2020. Going forward, the mail order segment is expected to be the fastest growing segment in the rituximab biosimilar market segmented by distribution channel, at a CAGR of 34.0% during 2020-2025.

North America was the largest region in the rituximab biosimilar market, accounting for 48.0% of the total in 2020. It was followed by Western Europe and Eastern Europe, and then the other regions. Going forward, the fastest-growing regions in the rituximab biosimilar market will be South America, and Asia Pacific, where growth will be at CAGRs of 36.7% and 29.2% respectively. These will be followed by North America, and Western Europe where the markets are expected to grow at CAGRs of 18.3% and 13.6% respectively.

The rituximab biosimilars market is expected to be negatively impacted due to the spread of COVID-19. Restrictive containment measures involving social distancing, remote working, and the closure of industries and other commercial activities resulted in operational challenges. The entire supply chain has been disrupted, impacting the market negatively. Further, biopharmaceuticals and biosimilar manufacturers have shifted their resources towards finding a treatment for the coronavirus, which has delayed the production of new and existing rituximab biosimilar products. Some biosimilar developers have also entered their non-biosimilar products into the development stage in efforts to find a treatment for COVID-19. The development of some rituximab biosimilars in the pipeline are also halted as companies continue trying to develop biosimilars that can combat the virus.

The rituximab biosimilar market is highly concentrated, with a small number of large players dominating the market. The top five competitors in the market made up 92% of the total market in 2019. Major players in the market include Teva Pharmaceuticals, Novartis AG, Pfizer, BIOCAD, and Shanghai Henlius Biotech, Inc.

The top opportunities in the rituximab biosimilar market segmented by application will arise in the non-Hodgkin's lymphoma segment, which will gain $565.9 million of global annual sales by 2025. The top opportunities in the segment by distribution channel will arise in the hospital pharmacy segment, which will gain $1,302.3 million of global annual sales by 2025. The rituximab biosimilar market size will gain the most in the USA at $896.2 million.

Market-trend-based strategies for the rituximab biosimilar market include leveraging revised FDA regulations for biosimilar drug development, establishing strategic partnerships and collaboration agreements with the large players to expand their research and developments activities in new drug developments, and investing extensively in R&D activities for the development of effective and innovative biosimilars.

Player-adopted strategies in the rituximab biosimilar market include cost-reduction in manufacturing, marketing approvals from respective regulatory bodies, and establishment of new manufacturing facilities and strategic collaboration, license & distribution agreements with existing players in the industry.

To take advantage of these opportunities, the publisher recommends the rituximab biosimilars manufacturing companies to consider investing in the development of the new rituximab biosimilars, work on strategic alliances for research & development to speed up the drug discovery and manufacturing process, expanding activities to the European Unions and other emerging markets to gain market share, offer competitively priced and cost effective drugs to attract the users, leverage online pharmacies and business websites to reach targeted physicians and customers, among other strategies.

Note: Product cover images may vary from those shown
  • Teva/Cellitron
  • Novartis AG
  • Pfizer
  • BIOCAD
  • Shanghai Henluis Biotech Inc.
  • Sandoz
  • Innovent Biologics, Inc
  • Sinocelltech
  • Cadila Pharmaceuticals
  • Hetero Drugs Limited
  • Dr Reddy’s Laboratories
  • Shanghai Fosun Pharmaceutical(Group)Co., Ltd.
  • Reliance Life Sciences, India
  • Zenotech Laboratories
  • NAPP Pharmaceuticals Limited
  • Mundipharma Deutschland GmbH & Co. KG
  • Celltrion
  • MABION S.A.
  • Janssen Pharmaceutical
  • Amgen
  • Coherus BioSciences
  • Mylan
  • mAbxience
  • Aryogen Biopharma
  • TR-Pharm
  • Hikma Pharmaceuticals plc
Note: Product cover images may vary from those shown

Loading
LOADING...

Adroll
adroll